Short VUZI. Fraud.

March 16, 2018
  • This report is the opinion of the author. The author is short VUZI.
  • Vuzix recently used an undisclosed stock promotion involving dozens of mainstream media outlets to artificially inflate the share price and volume, and then raise $30 million
  • Photos of leaked documents from IRTH Communications show IRTH bragging to potential clients that it was responsible for more than 30 articles from mainstream media outlets which all simultaneously erupted in connection with Margolis’ “Alexa ruse”. These specific IRTH sponsored articles were conspicuous in that they offered effusive praise for Vuzix but appeared as standard news on dozens of mainstream sites
  • The information contained in the articles and product reviews was flat out wrong, but was then repeatedly re-broadcast by Vuzix (esp. Margolis) in order to inflate the stock. Margolis made heavy use of social media, adding the $VUZI ticker next to the sponsored articles
  • Vuzix’s “Blade” is little more than a low tech mock-up which serves as a prop for journalists to conduct sham reviews. When these journalists “reviewed” the product at CES, neither the Alexa feature nor the browser were functioning – not for any of the journalists. Yet these same journalists then widely touted the device in their mainstream bylines, overwhelmingly on the basis of the Alexa features that actually don’t exist !
  • Matt Margolis conceals his past employment by multiple fraudsters who had also been behind undisclosed promotions on Vuzix for years. Margolis’ former employer Mark Gomes was shut down under SEC fraud proceedings in September just after running his latest promotion on Vuzix
  • With a separate promoter, Margolis was actively promoting Cemtrex and other IRTH clients without disclosing that he was being paid via IRTH Communications. Cemtrex subsequently collapsed.
  • Vuzix’s recent “Alexa ruse” was actually a recycled ploy that Margolis had used on Vuzix in 2016,while he was still employed by outside promoters. Just like with the “GoPro ruse” in 2016, adding Alexa functionality costs nothing and can be done in just one hour by downloading a simple developer kit. Margolis then uses this non-event as a pretense to run a stock promotion
  • Over the past 11 months, we have seen a very visible acceleration in SEC enforcement against this exact type of fraud. The recent undisclosed IRTH promotions were now too blatant and were then used for an immediate $30 million capital raise at $9.95. Investors in that offering ended up seeing nearly immediate losses after the pump campaign stopped.

 

Summary

  • In Oct 2017, shares of ABEO hit a new high of $19.55 following the release of seemingly positive data in its clinical trial for MPS-III.
  • ABEO quickly used that strength to raise money in an equity offering at $16 in October.
  • But when additional data was released last week, ABEO quickly began to plunge every day.
  • “Smart money” investors now realized that Cohort 1 data had been badly manipulated to show optimal results.
  • Out of a three person Cohort, one patient was given an arbitrary “floor score” for a cognitive test – precluding any real chance of further declines in cognitive ability. Another patient was removed from the trial altogether.  
  • This information was not made clear in October at the time of the equity offering
  • In addition, Cohort 2 data was visibly mixed, with the strongest results coming from a disputed test method and with very negative indications coming from the industry standard test
  • The leading industry journal specifically recommends two different tests than the one being used by ABEO. The non recommended test is the one which analysts continue to cite as indication of strong results.
  • The investors who have figured this out have been selling heavily every day since that data was released on Feb 8th.
  • Yet sell side analysts continue to put positive spin on the results by focusing on a single “outlier” to explain negative results.

Summary: In over 20 years SSTI has never generated profits or meaningful cash. Recent IPO simply allows VCs to finally exit positions. Dec 4th lockup expiration on 8 million shares Reams of independent data and test use confirm that SSTI ‘s technology simply doesn’t work. Period. Customers repeatedly describe overwhelming failure rate. Aggressive tactics by…

Read More

Summary On Tuesday, Cemtrex fell 13% on huge volume. On the preceding trading day, Cemtrex’s banker Source Capital quietly had its SEC and FINRA registrations terminated following multiple violations. Over $1 million has been paid to notorious stock promoters sending CETX soaring from below $2. Heavy undisclosed selling by CETX insiders during paid promotion. DOCUMENTS:…

Read More

Summary Nymox withheld the data that Phase 3 trials of its only drug had failed for 6-12 months after management knew of the failure. During this time, Nymox issued bullish press releases while management continued to aggressively dump stock without timely SEC disclosure. Offshore anonymous Panamanian finance deals; auditor, legal counsel, bankers ALL closely tied…

Read More

Summary Since I last highlighted fraud concerns at Osiris, the stock has fallen by 40%. I expect an additional 50% drop based on new catalysts. The CEO has since resigned unexpectedly. Osiris is unable to file its 10K and has now received a NASDAQ deficiency notice. Last week, Osiris’ head of sales has just been…

Read More

Summary Air Media rebounded on Tuesday as retail investors “played the bounce” in anticipation of a company response. After the company responded on Wednesday, the stock opened lower, traded down and closed at the lows of the day, down 12%. Air Media has now disclosed new information which is pressuring the stock. We can now…

Read More

Summary Heavily promoted by multiple paid promoters (including undisclosed). Stock has spiked to an all-time high. Company is out of cash and is delinquent in its filings. Management with close connections to past frauds. Expect a very near-term financing to drop the stock by at least 30-40%. This article is the opinion of the author….

Read More

Summary Companies who pay for stock promotion should be avoided. Period. Sell side research is woefully deficient and predictably biased. With technology, you get what you pay for. Lack of institutional ownership is a strong predictor of failure. Share price is a poor predictor of ultimate success. This article is the opinion of the author….

Read More

Summary Advaxis stock has recently quadrupled from $3 to as high as $13. Management has a history of promotional and misleading activities, including heavy use of the Dream Team Group. Tumor response data for its lead candidate has been mis-presented to overstate effectiveness. ADXS-HPV has demonstrated notably inferior survival rates vs. alternatives. Over 3 million…

Read More

Summary CEO of Lion Biotech resigns following subpoena. Stock has fallen by 12% already. There is a wide web of parties with ties to Galena. Back in March, I highlighted the undisclosed paid stock promotions being run by the Dream Team Group in connection with CytRX (NASDAQ:CYTR) and Galena (GALE). In the wake of that scandal, we…

Read More

Summary ChinaBak recently soared from below $2.50 to $5.00 “news” that LG was entering the China EV market and on subsequent EV subsidy news from China. But ChinaBak is not even currently in the EV business and will likely derive zero benefit. Day traders are simply playing a dangerous game of greater fool. Creditors recently…

Read More

Summary Northwest Bio has been the subject of a massive promotional campaign which has seen the stock price soar. Many of the authors involved have close hidden ties to promotional firm MDM Worldwide and / or Redfish Creative. In some cases, authors have used fictitious identities and fake credentials within healthcare or finance. In fact…

Read More

Summary A recent report from Vista Partners sent OHRP soaring by 60%. The contents, including a $31 price target, was provided and paid for by Ohr management. Ohr stock had just collapsed to as low as $6.86 due to a recent failure of its drug in clinical trials. Squalamine was previously owned by Genaera Pharma….

Read More

Summary ProActive Capital seeks to provide clarification. The firm says it was unaware of the Dream Team website. ProActive has now severed ties with Tech Guru, and says the contract in the article was not the actual contract with Tech Guru. Prior to my article last week discussing ProActive Capital, I approached that firm for comment. However,…

Read More

This article is the opinion of the author. Nothing herein comprises a recommendation to buy or sell any security.  The author is short INO and UNIS. The author may choose to transact in securities of one or more companies mentioned within this article within the next 72 hours.   Note #1: Prior to publishing this…

Read More

Note: At least 13 recent articles covering CytRx have been removed from circulation at Seeking Alpha, the Wall Street Cheat Sheet, Motley Fool and Forbes. Many were removed in just the past two days. A list of these removed articles is shown at the bottom of this article. The author has preserved PDF copies of…

Read More

Investment considerations As bulls and bears debate their longer term expectations for revenues at Unilife, many have missed the fact that there are near term catalysts which can be expected to have a very certain impact on the share price well before these longer term forecasts have a chance to play out. Investors should also…

Read More

Organovo Holdings (ONVO) has doubled in the past two weeks and now sports a market cap in excess of $1 billion with a share price of $12-13. The company has 58 cents per share in cash following an equity raise at $4.50 in July. Aside from that, total assets for the company amount to just $1 million. The company currently has no products on the market, but hopes to launch a 3D liver assay in December 2014. However, detailed market analysis reveals that total market potential for this product is only a few million dollars. There are already competing 3D liver assays on the market which sell for as little as $1,750. Swiss company Insphero reveals that the market size for these assays is at most a few thousand units per year. The stock has recently doubled due to a tremendous wave of articles which suggest that Organovo is on the cusp of generating hundreds of millions of dollars in near term revenues. The stock is held 93% in retail hands and has no institutional research coverage. As investors realize that the best case if for $3-5 million in revenues over the next 3 years, the stock should be due for a meaningful correction. Meanwhile, insiders have been selling millions in stock and have filed a massive S8 registration statement by which they can award themselves 11 million more shares, valued at $130 million. Additional concerns are highlighted herein. In the near term, Organovo should be expected to drop by around 50%, returning to the $5-7 level where it was just two weeks ago.